Chalette Lambert-Swainston

Internal Medicine

1707 W Charleston Blvd Ste 100
Las Vegas, NV 89102

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 7 publications

HSR25-187: Meta-Analysis of Phase III Randomized Controlled Trials to Evaluate the Risk of Gastrointestinal Adverse Events in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab.

HSR25-187: Meta-Analysis of Phase III Randomized Controlled Trials to Evaluate the Risk of Gastrointestinal Adverse Events in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 28, 2025

HSR25-152: Incidence of Hematologic Adverse Events in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab: A Meta-Analysis of Phase III Randomized Controlled Trials.

HSR25-152: Incidence of Hematologic Adverse Events in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab: A Meta-Analysis of Phase III Randomized Controlled Trials.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 28, 2025

HSR25-171: Risk of Health-Related Quality of Life (HRQOL) Events in Patients with EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab: A Meta-Analysis of Phase III Randomized Controlled Trials.

HSR25-171: Risk of Health-Related Quality of Life (HRQOL) Events in Patients with EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab: A Meta-Analysis of Phase III Randomized Controlled Trials.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 28, 2025

HSR25-172: Meta-Analysis of Phase 3 Randomized Controlled Trials to Evaluate the Incidence of Infectious Adverse Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin.

HSR25-172: Meta-Analysis of Phase 3 Randomized Controlled Trials to Evaluate the Incidence of Infectious Adverse Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 28, 2025

HSR25-143: Meta-Analysis of Phase 3 Randomized Controlled Trials to Evaluate the Incidence of Systemic Toxicities in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin.

HSR25-143: Meta-Analysis of Phase 3 Randomized Controlled Trials to Evaluate the Incidence of Systemic Toxicities in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 28, 2025

Case report: Complete response of recurrent locally advanced basal cell carcinoma following addition of vismodegib to neoadjuvant cemiplimab therapy.

Case report: Complete response of recurrent locally advanced basal cell carcinoma following addition of vismodegib to neoadjuvant cemiplimab therapy.

Journal: Frontiers in oncology

Published: September 23, 2024

Spontaneous secondary pneumothorax due to cannabis-induced bullous lung disease: a case report.

Spontaneous secondary pneumothorax due to cannabis-induced bullous lung disease: a case report.

Journal: Annals of medicine and surgery (2012)

Published: April 17, 2023

Showing 1-7 of 7

Last Updated: 09/26/2026